跳到正文
原文
Nature 健康护理主题·· 2026-10-07AI 评分55

2020至2026年虫媒病毒风险与应对变化的叙述性综述

Changes in arbovirus risks and responses from 2020 to 2026

AI 导读

一篇叙述性综述检索2020年1月1日至2026年6月30日的文献与公共卫生指南,归纳虫媒病毒风险与应对的五项变化。登革热仍是最广泛的虫媒病毒病,2024年全球报告超过1440万例病例、逾5.2万例重症和约1.1万例死亡。

正文

We conducted a narrative review of literature and public health guidance on arboviruses and their vectors published from January 1, 2020, through June 30, 2026. The review aimed to identify major developments since a prior 2020 overview, emphasizing findings relevant to clinicians, surveillance programs, vaccine and vector-control policy, and public health practice.

We searched PubMed/MEDLINE and Google Scholar using combinations of terms related to arboviruses, pathogens, vectors, surveillance, diagnostics, vaccines, therapeutics, and vector control. Search terms included combinations of “arbovirus”, “arthropod-borne virus”, “dengue”, “chikungunya”, “Zika”, “yellow fever”, “West Nile”, “Oropouche”, “Mayaro”, “Japanese encephalitis”, “Powassan”, “La Crosse”, “Aedes aegypti”, “Aedes albopictus”, “Culex”, “Culicoides”, “vector competence”, “range expansion”, “genomic surveillance”, “wastewater”, “environmental DNA”, “diagnostics”, “multiplex PCR”, “vaccine”, “therapeutic”, “Wolbachia”, “sterile insect technique”, “spatial repellent”, “pyriproxyfen”, and “indoor residual spraying”. Searches were supplemented by reference-list review and targeted review of surveillance, guidance, and regulatory documents from the World Health Organization, Pan American Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, U.S. Food and Drug Administration, and European Medicines Agency.

We prioritized primary studies, clinical trials, systematic reviews and meta-analyses, major surveillance reports, policy recommendations, and regulatory documents that described substantial changes since 2020 or had direct implications for clinical care, surveillance, vaccination, therapeutics, vector ecology, or vector control. We excluded articles outside the 2020–2026 period unless needed for historical context, articles not directly relevant to human arboviral disease or vector-borne public health practice, studies focused only on basic virology or animal models without clear clinical or public health relevance, and duplicate or superseded guidance documents. Preprints were identified through Google Scholar, reference-list review, and coauthor expertise rather than a separate systematic search of preprint servers. They were considered only when they addressed rapidly evolving developments not yet represented in peer-reviewed literature and were identified as preprints in the reference list.

One author (Z.J.M.) conducted the initial searches and screening. All coauthors reviewed selected evidence within their areas of expertise and suggested additional sources. Final inclusion was based on relevance to the five themes highlighted in this review and consensus among the authors. Because this was a narrative review rather than a systematic review or meta-analysis, we did not perform duplicate screening, formal risk-of-bias assessment, exhaustive evidence mapping, or pooled quantitative synthesis.

Change 1: Dengue still dominates, but the resurgence and expansion of other arboviruses remain a threat

Dengue remains the most widespread arboviral disease. In 2024, more than 14.4 million dengue cases, including over 52,000 severe cases and about 11,000 deaths, were reported globally—the highest annual totals in modern records and a major strain on health systems3. Dengue virus (DENV) serotype circulation has also shifted, with re-emergence of DENV-3 and increased detection of DENV-4 in parts of the Americas4,5. Genomic analyses suggest that many recent epidemics have been driven by overlapping lineages rather than by a single variant6,7. Intense dengue seasons therefore rarely have a single explanation. They can reflect the combined effects of co-circulating serotypes and lineages, changing population immunity, and ecological conditions that favor vector abundance.

Immunologic studies have further clarified why some DENV infections progress to severe disease. Prior DENV infection is known to influence the risk of severe disease after subsequent infection. Newer work suggests that prior Zika virus (ZIKV) infection and qualitative features of the antibody response, including IgG afucosylation, may also shape risk8,9,10. Nonstructural protein 1 (NS1) also contributes to vascular leak and remains an important diagnostic target, reinforcing guidance to use NS1- or RNA-based tests early in illness when available11.

Chikungunya has re-emerged as a major clinical and public health problem. Since 2020, large outbreaks have caused hundreds of thousands of cases in Brazil, Paraguay, Bolivia, the Indian Ocean region, and parts of South and Southeast Asia12. Many patients experience disabling arthralgia and fatigue after acute infection, sometimes lasting months to years13. Long-term morbidity is therefore a substantial part of chikungunya’s burden, even when mortality is low. Viral changes that enhance replication in Ae. albopictus are thought to have contributed to transmission in temperate regions14,15,16, while recent longitudinal cohorts and mechanistic studies have better characterized the frequency, persistence, inflammatory phenotypes, and biology of chronic chikungunya sequelae17,18.

Since 2020, Zika and yellow fever viruses have caused fewer large outbreaks than dengue or chikungunya but remain clinically important. ZIKV continues to circulate at low levels, with sporadic detections in Africa, Asia, and the Americas19,20. Long-term follow-up has documented sustained neurologic and developmental challenges in children with congenital Zika syndrome, and newer studies suggest that even some children with in utero exposure without classic congenital Zika syndrome may remain at risk for developmental delay21,22. Yellow fever outbreaks in Africa and the Americas have likewise highlighted vulnerabilities where vaccination coverage has lagged, routine services have been disrupted, or vaccine supply has been constrained23,24. A single dose of yellow fever vaccine remains highly protective.

Oropouche, Mayaro, and other watch-list viruses have become more prominent. In 2024–2025, Oropouche virus caused large outbreaks in the Americas beyond its historic Amazon range, including in urban areas, with substantial spatial heterogeneity in risk shaped by demographic, climatic, and environmental conditions25. Most cases are mild, but complications can include vertical transmission, possible adverse pregnancy outcomes, neurological manifestations, and rarely, death26,27. In urban and peri-urban settings, transmission is driven mainly by the biting midge Culicoides paraensis28. Mayaro virus still circulates mainly in forest and rural transmission cycles29, but laboratory evidence of efficient transmission by Ae. aegypti and Ae. albopictus raises concern about urban spillover potential30,31. Because early presentations overlap with dengue and other nonspecific acute febrile illnesses, these infections are likely to be misclassified without molecular or reliable serologic diagnostics. Arboviral diversity is also evident beyond the tropics: in the United States, Powassan virus disease remains rare but has increased in recent years, while La Crosse virus continues to cause recurrent seasonal neuroinvasive disease, particularly among children32,33. Clinicians should use the patient’s clinical presentation and epidemiologic risk factors such as travel history to guide testing considerations for dengue as well as less commonly diagnosed arboviral infections. Consultation with public health authorities may also be beneficial when rare arboviral infections are suspected to help determine the most appropriate diagnostic testing. For example, suspect case definition criteria have recently been developed for Oropouche virus and include compatible illness with travel to an area with transmission within two weeks of initial symptom onset, recognizing that patients may experience recurrent nonspecific febrile illness or, less frequently, recurrent neurologic symptoms28,34,35.

Current understanding of arboviral risk reflects both transmission and the capacity to detect it36. Because many infections are asymptomatic or clinically nonspecific, observed patterns depend on which clinical presentations prompt testing, which diagnostic assays and case definitions are used, how broadly vector and genomic surveillance is conducted, and how completely cases are reported. Broader, integrated surveillance can reveal epidemiologic shifts, genetic turnover, unusual transmission events, and geographic spread that remain undetected where capacity is limited, even when competent vectors are present.

Recent events show what this means in practice. In the United States, genomic investigation identified the first known human infection involving West Nile virus lineage 3, detected together with lineage 1b in a patient with neuroinvasive disease37. In northern Italy, genomic surveillance identified a newly introduced West Nile virus lineage 1 strain in 2021 and documented its rapid spread in a region already co-endemic for lineage 238. The 2022 Japanese encephalitis outbreak on the Australian mainland, which included the first locally acquired mainland cases detected since 1998, was recognized through coordinated human, animal, and vector surveillance and indicated geographic expansion rather than previously unrecognized longstanding transmission39.

Taken together, these trends argue against a narrow focus on familiar arboviruses or interpretation of raw case counts in isolation. For clinicians and public health programs, the practical challenge is no longer only rising dengue burden, but recognizing a wider and shifting set of clinically similar infections—many of which may be misclassified or missed where surveillance and diagnostic capacity are uneven—and interpreting trends using clinical, laboratory, genomic, entomological, and severity data together.

Change 2: Surveillance and diagnostics are becoming more anticipatory

A second major change since 2020 is the movement toward surveillance and diagnostic tools that can identify vector presence, transmission risk, or outbreaks earlier than routine case reporting alone. Traditional case and vector surveillance remain the backbone of arboviral control. Some newer tools are approaching operational decision support, while others remain research-based, in pilot use, or limited to specialized settings. Their value depends on field validation, affordability, local calibration, and integration into routine surveillance and response systems.

Integrated risk maps and outbreak forecasting systems are among the tools closest to operational use. Although related, they answer different operational questions. Risk maps primarily identify where transmission risk or vulnerability is concentrated, using combinations of epidemiologic, entomologic, demographic, environmental, mobility, and other surveillance data to guide geographically targeted surveillance, vaccination, and resource allocation2,40. Forecasting systems add an explicit future time horizon. D-MOSS in Vietnam combines recent dengue case counts with seasonal climate forecasts, Earth-observation data, and sociodemographic predictors to generate monthly province-level forecasts of dengue incidence and outbreak-threshold exceedance one to six months ahead41. Its prospective evaluation illustrates the movement from retrospective modeling toward operational decision support, although performance varies by setting, season, lead time, and threshold choice. Routine surveillance of dengue diagnosed in travelers after their return to the United States provides a different but complementary signal. It uses likely countries of exposure to identify sustained increases in destination-specific risk and can complement local reporting where official data are delayed or incomplete42.

Other approaches remain earlier in the research-to-implementation pathway. Environmental DNA methods are being explored for detecting Aedes, Culex, and other vector species in aquatic habitats, but their public health value remains uncertain because sampling, laboratory capacity, training requirements, action thresholds, and links to adult mosquito abundance or transmission risk remain incompletely defined43,44,45. Computer-vision and machine-learning approaches are also being tested for entomological surveillance. AI-enabled smart traps may support faster mosquito detection and classification, while satellite, street-view, and drone imagery may help identify likely breeding sites, such as rooftop tanks, tires, and gutters46,47,48,49,50. However, performance varies by species, setting, image quality, training data, maintenance requirements, and local infrastructure, and few systems have been evaluated against traditional surveillance methodologies for sustained routine use or impact on outbreak response. These tools are best viewed as complements to routine surveillance rather than replacements for it.

Wastewater surveillance, scaled rapidly for SARS-CoV-2, is now being applied to arboviruses, but its role in public health practice remains uncertain. Several arboviruses, including dengue, chikungunya, and Zika, have been detected in wastewater, yet interpretation of these data is limited by poorly defined shedding dynamics, viral RNA degradation, and uncertain relationships between wastewater signals and incident human infection51,52,53,54. Current methods also cannot distinguish travel-associated from locally acquired infections, and sewer catchments may exceed the geographic scale at which vector-control interventions are implemented51. For arboviruses with non-human amplifying hosts, such as West Nile and Japanese encephalitis viruses, wastewater detections may reflect animal rather than human infections, further complicating interpretation55. Studies are needed to determine when wastewater signals are actionable, but possible use cases include early detection of novel pathogens introduced into new areas, which could trigger enhanced clinical and vector surveillance, and targeted agricultural applications, such as monitoring epizootic signals of Japanese encephalitis in pig-farm effluent56.

Diagnostics have also advanced, but access remains uneven. High-sensitivity rapid tests, multiplex PCR platforms, next-generation sequencing, and multiplex serologic approaches are increasingly available in referral, research, and tertiary-care settings, while lower-cost locally produced assays and point-of-care multiplex platforms remain under development or early implementation in many settings57,58,59. These tools make it increasingly feasible to confirm dengue, chikungunya, or related arboviral infections rather than rely on clinical diagnosis alone, improving case management and surveillance where tests are available. This is particularly important for immunocompromised patients, including those receiving B-cell-depleting monoclonal antibodies such as rituximab, who are at increased risk of severe arboviral disease and may have blunted serologic responses60. More broadly, the value of these assays depends on testing the right patients early in illness and matching the diagnostic approach to timing of presentation. Broader public health impact will require affordability, availability, quality assurance, and integration into routine clinical and reporting systems beyond tertiary centers.

Change 3: Arboviral vaccines are moving from promise to practice, while therapeutics remain limited

A third major change since 2020 is the shift from vaccine development and emergency-use evidence toward programmatic decision-making for several arboviral vaccines, alongside more limited progress in therapeutics. Products once in early development are now licensed, prequalified, or entering phase 3 trials, bringing implementation, safety, and evaluation questions to the foreground.

For dengue, vaccine policy depends on local transmission intensity, age-specific seroprevalence, serotype-specific performance, and post-licensure safety data. CYD-TDV had been recommended only for persons with evidence of previous dengue infection because vaccination of seronegative individuals was associated with increased risk of severe dengue after subsequent infection. Pre-vaccination screening was therefore central to safe use but created major operational barriers, including test availability, cost, specificity, cross-reactivity, and consequences of false-positive or false-negative results61,62. The manufacturer has stopped production of CYD-TDV, with remaining doses expiring in 202661,62. The live-attenuated TAK-003 vaccine has been prequalified by WHO and recommended for routine use in children aged 6–16 years in high-transmission settings, but WHO does not recommend programmatic use in low-to-moderate transmission settings until the efficacy-risk profile for DENV-3 and DENV-4 in seronegative persons is better characterized63,64. TV005/Butantan-DV was approved in Brazil in late 2025 as a single-dose tetravalent dengue vaccine65,66. However, in June 2026, Brazil temporarily discontinued the current Butantan-DV vaccination strategy as a precaution after rare, unexpected warning-sign events and serious adverse events were detected through pharmacovigilance; Anvisa announced an expert panel and requested additional data to reassess the vaccine profile67. This pause does not establish causality, but it underscores the need for active post-licensure safety surveillance and transparent benefit-risk reassessment.

Yellow fever vaccination presents a different implementation challenge: the standard vaccine is highly effective, but supply constraints can limit outbreak response. Fractional dosing predates 2020, but recent follow-up and trials have clarified the durability and limitations of this strategy. During the 2016 yellow fever outbreaks in Angola and the Democratic Republic of the Congo, global stockpile constraints led to the use of one-fifth-dose vaccination as a dose-sparing strategy68. Follow-up studies from Kinshasa showed that most recipients retained detectable neutralizing antibody titres 5 years after fractional-dose vaccination, supporting the durability of the immune response68. Several studies have shown that a fractional dose of approximately 500 IU is sufficient to achieve seroconversion rates similar to those achieved with the standard dose (13,808 IU) in adults 69,70,71. However, evidence is limited for certain populations including young children and individuals with impaired immune responses such as those living with HIV or with autoimmune disease, based on data from non-inferiority and immunogenicity studies72,73,74. Fractional dosing in healthy adults can extend vaccine supply during emergency response but remains a dose-sparing strategy for supply-constrained outbreak settings rather than a substitute for routine full-dose vaccination.

For chikungunya, the single-dose live-attenuated vaccine VLA1553/IXCHIQ received its first regulatory approvals in 2023–2024, but post-marketing safety reports, particularly among older adults and people with underlying medical conditions, led to major regulatory reassessment75,76,77. In the United States, the FDA suspended the biologics license in 2025, and Valneva subsequently withdrew the U.S. biologics license application and investigational new drug application in early 202676,78. Regulatory responses outside the United States have differed; for example, European regulators retained authorization while emphasizing use only when chikungunya risk is substantial and after careful benefit-risk assessment77. A non-live virus-like particle vaccine, PXVX0317/VIMKUNYA, was approved in the United States and European Union in 2025, and U.S. recommendations now address its use for selected travelers and laboratory workers79,80. Additional live-attenuated, VLP, and mRNA platforms remain in development81,82,83. Real-world evaluations will need to assess effectiveness, durability of protection, and safety across age and comorbidity groups. They should also determine whether vaccines can be deployed early enough to provide meaningful benefit during rapidly accelerating outbreaks.

Together, these examples show that moving arboviral vaccines into practice requires more than regulatory approval. Vaccine policy must be matched to local epidemiology and population immunity. It also requires active safety surveillance, real-world effectiveness evaluation, transparent benefit-risk reassessment, and the capacity to revise recommendations as evidence evolves. Programs must address contraindication screening, delivery logistics, affordability, and equitable access to sustain sound policy and public confidence.

Therapeutic options, by contrast, remain largely limited to supportive care, although candidate small-molecule antivirals and monoclonal antibodies for dengue and other arboviruses continue to advance84,85. In 2026, BARDA launched a $100 million multistage prize competition to accelerate the development of broad-spectrum small-molecule antivirals targeting Togaviridae and Flaviviridae, from early concepts toward investigational new drug readiness86. These efforts remain investigational and have not changed routine clinical care, so prevention, early diagnosis, and careful management of complications remain the primary tools for clinicians.

Change 4: Vector range expansion and ecological flexibility are being documented more clearly

A fourth development is stronger evidence that vectors are established across broader geographies, showing ecological and behavioral flexibility at range margins. Ae. aegypti and Ae. albopictus have continued to expand across parts of Europe, the Americas, and Africa, consistent with surveillance data and habitat-suitability models linking spread to climate, urbanization, and human movement; Ae. aegypti is now established in the Las Vegas metropolitan area despite its arid climate87,88,89,90. Other invasive species, including Aedes koreicus and Aedes japonicus, have been documented in multiple European countries91,92. Although generally considered secondary or less well-defined arboviral vectors compared with Ae. aegypti, their spread extends potential transmission risk into peri-urban and temperate settings once considered low risk93,94. In the Americas, establishment of Ae. scapularis in mainland Florida and detection of invasive Ae. vittatus in Caribbean islands further broaden the range of anthropophilic Aedes species that could contribute to arboviral transmission, although their epidemiologic roles remain uncertain95,96.

Culex mosquitoes have also become increasingly important in this changing landscape. They have long sustained enzootic and epidemic transmission of West Nile virus in the Americas, Europe, Africa, and the Middle East, and Japanese encephalitis virus across much of Asia and the western Pacific97. In recent years, European surveillance has documented locally acquired West Nile virus infections in regions without previous reports of human disease, underscoring that recognized Culex-borne transmission risk is widening in some settings98. These patterns likely reflect a combination of vector suitability, avian host ecology, climate, and surveillance rather than vector expansion alone. Although classically considered malaria vectors, Anopheles species have also been implicated in transmission of selected arboviruses, including O’nyong-nyong and Rift Valley fever viruses, but vector-competence data remain sparse for most arbovirus-Anopheles pairings, leaving an important gap in transmission-risk assessment99,100,101.

New evidence also points to behavioral and physiologic flexibility. Artificial light may lengthen windows of human-vector contact by extending evening biting by typically day-active Ae. aegypti and, in Cx. pipiens, averting diapause and maintaining later-season biting and reproduction102,103. Interrupted blood meals are followed by rapid re-feeding, enabling mosquitoes to feed on multiple hosts; arbovirus infection may also modify host-seeking and blood-feeding behavior, although effects appear subtle and context-dependent104,105. Laboratory studies also show that Aedes larvae tolerate higher salinity and a wider range of breeding sites than previously appreciated106,107. Field surveillance has documented Aedes breeding at higher altitudes than conventional risk maps suggested, including Ae. albopictus around 1800 m in eastern Turkey108 and Ae. aegypti at more than 2900 m in Sucre, Bolivia109. Genomic work from Nepal likewise shows Ae. aegypti established in cooler highland communities along an altitudinal gradient, with evidence of local adaptation110. These findings indicate that coastal, peri-urban, and highland foci can no longer be assumed to be low risk without local entomologic and epidemiologic surveillance.

Change 5: Aedes-focused vector control has moved from proof-of-concept to proof-at-scale for dengue

A fifth change since 2020 is that selected Aedes-focused vector-control tools now have evidence for reducing dengue risk at citywide or large programmatic scale. Some may also reduce other Aedes-borne arboviruses, but the strongest human disease evidence remains for dengue. Evidence strength varies across tools, and entomologic suppression does not always translate into measurable disease reduction. Feasibility, cost, environmental considerations, community acceptability, and management requirements also differ substantially across interventions. Still, Aedes control is beginning to move beyond reliance on reactive spraying toward integrated packages that reduce mosquito abundance, vector competence, or human-vector contact.

Wolbachia-based population replacement in Ae. aegypti is the clearest example. Cluster-randomized trials have shown that releasing mosquitoes infected with the wMel strain can establish Wolbachia in local mosquito populations and reduce virologically confirmed dengue and related hospitalizations by roughly three-quarters in intervention clusters111. Subsequent large-scale deployments have shown substantial real-world reductions in dengue incidence, and cost-effectiveness analyses suggest medium-term savings in densely populated urban areas112. However, experience in Brazilian cities suggests that impact depends on durable Wolbachia establishment and implementation quality, with sustained effects reported in Niterói but weaker persistence and more heterogeneous implementation in Rio de Janeiro113. Wolbachia strain choice also matters: wMel has performed well in many settings, whereas wAlbB may be more robust under sustained high temperatures114,115. Because viral blocking may vary across Wolbachia and DENV serotypes, programs should plan for post-deployment monitoring rather than assume identical effectiveness everywhere116. Key questions are now operational: how to implement and sustain releases with limited local capacity, how durable impact will be under changing climate and transmission conditions, and how to integrate Wolbachia with vaccination and other interventions to manage residual risk, including possible shifts in population immunity over time117.

Male-release suppression strategies, including sterile insect technique, incompatible insect technique, and self-limiting genetically modified mosquitoes, have also expanded from pilots to larger field programs, with repeated demonstrations of substantial Ae. aegypti and, in some settings, Ae. albopictus suppression in treated areas118,119. Unlike Wolbachia population replacement, which aims to make mosquito populations less competent to transmit virus, these approaches suppress mosquito populations directly through repeated programmed releases. The strongest disease-endpoint evidence comes from Singapore, where a combined incompatible insect technique-sterile insect technique approach using Wolbachia-infected, irradiated male mosquitoes has been associated with substantial dengue reductions, including approximately 71–72% protective efficacy after several months of exposure in a 2026 cluster-randomized test-negative trial120,121,122. These findings make male-release suppression one of the better-supported Aedes-control approaches for human dengue outcomes. Like population-replacement programs, broad implementation will require sustainable mass-production and release infrastructure, quality-control systems, financing, and integration with other arboviral-control interventions. Some suppression platforms additionally require highly reliable sex separation and irradiation and may depend on continued releases to maintain impact.

Another emerging area-wide approach is mosquito-disseminated pyriproxyfen, which uses mosquitoes to deliver larvicide to hard-to-reach breeding sites. In a large pragmatic trial in Belo Horizonte, Brazil, deployment was associated with a net 29% decrease in dengue incidence in intervention neighborhoods and a 21% decrease in adjacent buffer neighborhoods, suggesting direct and neighborhood-level spillover effects123. As with other larvicide-based strategies, effectiveness depends on correct implementation, coverage, persistence in breeding sites, and continued susceptibility to the insecticide; monitoring for unintended environmental or non-target effects is also important.

Traditional and household-level tools have also been evaluated across a broader evidence base. Systematic review evidence indicates that interventions targeting immature mosquito stages, and combined interventions targeting both immature and adult stages, often produce strong entomologic effects, whereas dengue outcomes are more variable and harder to demonstrate consistently124. Long-lasting insecticide-treated screens on doors and windows have shown durable reductions in indoor Ae. aegypti and lower household risk of exposure to arbovirus-infected mosquitoes125. Targeted indoor residual spraying (TIRS), which applies long-lasting insecticides to indoor resting surfaces, illustrates the same need to measure both entomologic and epidemiologic endpoints. In a 2025 cluster-randomized trial in Mérida, Mexico, TIRS reduced indoor Ae. aegypti density by 59%, but did not significantly reduce laboratory-confirmed symptomatic Aedes-borne disease in the participant cohort; geolocated surveillance data suggested a possible 24% community-level effect126. These findings suggest that even substantial reductions in indoor adult mosquitoes may be insufficient to reduce measured disease consistently when transmission is intense, exposure occurs outside treated homes or clusters, routine vector control is deployed in both groups, or residual transmission remains high.

These gains sit within the constraints of insecticide resistance and environmental stewardship. Knock-down resistance mutations in Ae. aegypti are now widely reported, and multiple cities have documented sharply reduced Ae. aegypti mortality to pyrethroids127,128. At the same time, sustained rotation away from pyrethroids in some programs has restored susceptibility over several years, showing that resistance management can work when treated as a strategic priority129. For programs, the choice and sequencing of chemical tools should therefore be guided by local resistance profiles, appropriate dosing and timing, and attention to possible non-target and ecological effects rather than assumed to be static or universally applicable.

Evidence has also strengthened for household-level tools that individuals can deploy. Spatial repellents, which release insecticidal vapors, have reduced Aedes-borne virus infections in randomized trials, including in areas with pyrethroid-resistant mosquitoes130,131. In a cluster-randomized trial in Iquitos, Peru, a transfluthrin-based spatial repellent reduced Aedes-borne virus infection by 34.1%, providing one of the clearest demonstrations that a chemical intervention can affect a human infection endpoint rather than only mosquito indices130. Recent WHO recommendations for spatial emanators in malaria may help inform regulatory evaluation of related products, although Aedes-specific program guidance and disease-endpoint evidence are still needed132. Autocidal gravid ovitraps, which attract and trap egg-laying female mosquitoes, remain a promising complementary tool, with community studies in Puerto Rico showing sustained Ae. aegypti suppression and lower chikungunya and Zika risk where deployed at scale133,134,135.

For vector-control programs, the main change since 2020 is that Aedes control now has stronger disease-endpoint and implementation evidence across a wider set of biological, structural, environmental, and chemical tools. The practical question is increasingly how to select and combine tools with different mechanisms, infrastructure needs, environmental considerations, and evidence bases. Environmental management and breeding-site removal have low direct toxicity and can be implemented by households, communities, and municipalities, but require sustained participation and reliable water, waste, and housing systems. Larvicides and adulticides can be useful when breeding sites cannot be eliminated or during outbreaks, but require correct product selection, dosing, timing, resistance monitoring, and safeguards for non-target effects. Wolbachia replacement requires release infrastructure, community engagement, and post-deployment monitoring, whereas male-release suppression approaches are species-specific and non-insecticidal but require specialized production, quality control, and repeated releases. Newer evidence also highlights the need to evaluate impact over multiple seasons because transmission intensity, serotype circulation, population immunity, climate, mobility, and coverage can change; a tool that reduces incidence in some years may have smaller or less visible effects in high-transmission years. Most recent innovation and disease-endpoint evaluation remains concentrated on dengue and other Aedes-borne diseases, whereas control of other arboviral vectors, including Culex spp., remains less transformed124,130.

来源:Nature 健康护理主题 · nature.com